Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2014

01.12.2014 | review

Post ASCO update 2014: head and neck cancer

verfasst von: Dr. Georg Pall, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this short review is to summarize some of the most important abstracts relating to the field of head and neck cancer presented at the ASCO Annual Meeting 2014. An Italian study group presented the first randomized phase III trial showing improved survival for patients with locally advanced squamous carcinoma of the head and neck using induction chemotherapy as an add-on to definitive local chemoradiotherapy or radiotherapy plus cetuximab. As these data are in contrast to already published trials and many questions around this treatment strategy remain unanswered, the definitive place of sequential therapies within the treatment algorithms remains to be defined. With the phase Ib data on the therapeutic efficacy of the anti-PD-1 antibody pembrolizumab released at the ASCO meeting we now for the first time have clinical evidence that modern immunotherapeutic strategies are worth studying in head and neck cancer. Finally, the phase III SELECT trial establishing lenvatinib as another therapeutic option in the treatment of radioiodine-refractory thyroid cancer will be discussed. In this study the experimental compound was shown to improve response rate and progression free survival with an acceptable toxicity profile.
Literatur
1.
Zurück zum Zitat Gregoire V, Lefebvre JL, Licitra L, Felip E, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;2(Suppl 5):v184–6. Gregoire V, Lefebvre JL, Licitra L, Felip E, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;2(Suppl 5):v184–6.
2.
Zurück zum Zitat Fabregas JC, Loaiza-Bonilla A, Talebi TN, et al. Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. Expert Rev Anticancer Ther. 2013;13(9):1065–72.PubMedCrossRef Fabregas JC, Loaiza-Bonilla A, Talebi TN, et al. Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. Expert Rev Anticancer Ther. 2013;13(9):1065–72.PubMedCrossRef
3.
Zurück zum Zitat Haddad R, O’Neill AO, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013;14(3):257–64.PubMedCrossRef Haddad R, O’Neill AO, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013;14(3):257–64.PubMedCrossRef
4.
Zurück zum Zitat Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216–25.PubMedCrossRef Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216–25.PubMedCrossRef
5.
Zurück zum Zitat Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43.PubMedCrossRef Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43.PubMedCrossRef
6.
Zurück zum Zitat Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol. 2014;32:5s (abstract 6004).CrossRef Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol. 2014;32:5s (abstract 6004).CrossRef
7.
Zurück zum Zitat Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013;18:288–93.PubMedCentralPubMedCrossRef Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013;18:288–93.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Ma J, Liu Y, Huang X, et al. Induction chemotherapy decreases the rate of distant metastases in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta analysis. Oral Oncol. 2012;48:1076–84.PubMedCrossRef Ma J, Liu Y, Huang X, et al. Induction chemotherapy decreases the rate of distant metastases in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta analysis. Oral Oncol. 2012;48:1076–84.PubMedCrossRef
9.
Zurück zum Zitat LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.CrossRef LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.CrossRef
10.
Zurück zum Zitat Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580–7.PubMedCrossRef Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580–7.PubMedCrossRef
11.
Zurück zum Zitat Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–9.PubMedCrossRef Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–9.PubMedCrossRef
12.
Zurück zum Zitat Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cancer and prostate cancer. Curr Oncol Rep. 2013;15:98–104.PubMedCrossRef Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cancer and prostate cancer. Curr Oncol Rep. 2013;15:98–104.PubMedCrossRef
13.
Zurück zum Zitat Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thor Oncol. 2014;9:144–53.CrossRef Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thor Oncol. 2014;9:144–53.CrossRef
14.
Zurück zum Zitat Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.PubMedCentralPubMedCrossRef Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42:268–74.PubMedCrossRef Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42:268–74.PubMedCrossRef
16.
Zurück zum Zitat Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32:5s (abstract 6011).CrossRef Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32:5s (abstract 6011).CrossRef
17.
Zurück zum Zitat Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety and economic evidence in radioactive-iodine refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013;23:392–407.PubMedCrossRef Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety and economic evidence in radioactive-iodine refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013;23:392–407.PubMedCrossRef
18.
Zurück zum Zitat Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive-iodine refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.PubMedCrossRef Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive-iodine refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.PubMedCrossRef
19.
Zurück zum Zitat Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitarget kinase inhibitor E7080 in advanced radioiodine (RAI) refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29 (abstract 5503). Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitarget kinase inhibitor E7080 in advanced radioiodine (RAI) refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29 (abstract 5503).
20.
Zurück zum Zitat Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicentre, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol. 2014;32:5s (abstract LBA6008).CrossRef Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicentre, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol. 2014;32:5s (abstract LBA6008).CrossRef
Metadaten
Titel
Post ASCO update 2014: head and neck cancer
verfasst von
Dr. Georg Pall, MD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0183-3

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe